01.08.2018
Biotest AG DE0005227235
DGAP-News: Biotest AG: Biotest has closed a transaction to sell all of its plasma collection centres in the United States to Grifols
DGAP-News: Biotest AG / Key word(s): Disposal
Biotest AG: Biotest has closed a transaction to sell all of its plasma
collection centres in the United States to Grifols
01.08.2018 / 18:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
PRESS RELEASE
Biotest has closed a transaction to sell all of its plasma collection
centres in the United States to Grifols
- Federal Trade Commission (FTC) approved sale of Biotest US Corporation and
its operating subsidiary
- Grifols paid USD 286 million for the acquisition of these assets
Dreieich, 01 August 2018. Biotest AG announces today that the approval of
the Federal Trade Commission (FTC), the U.S. antitrust authority, for the
sale of Biotest US Corporation and its operating subsidiary, Biotest
Pharmaceuticals Corporation (BPC), to the acquiring company Grifols Shared
Services North America Inc., a subsidiary of Grifols S.A. was granted. The
transaction has now been approved by all competent authorities.
With the approval of the FTC, the last remaining condition for the transfer
of shares in the US companies was met. With the sale, Biotest AG will
receive a purchase price of USD 286 million. Biotest AG has entered into the
agreement on the sale of its US companies in connection with the approval by
the US authority CFIUS (Committee on Foreign Investment in the United
States) of the voluntary takeover bid by Tiancheng (Germany) Pharmaceutical
Holdings AG, the acquisition company of Creat Group Corporation. Until the
sale could be completed, Biotest AG had transferred the US companies to an
US Trust.
About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and markets
immunoglobulins, coagulation factors and albumins based on human blood
plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of cancer of plasma cells and systemic lupus erythematosus which
are produced by recombinant technologies. Biotest has more than 1,600
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.
Greenberg Traurig, LLP acted as legal advisors for the transaction.
IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: [email protected]
PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: [email protected]
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart,
Tradegate
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and assumes
no obligation to do so.
---------------------------------------------------------------------------
01.08.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: [email protected]
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
710137 01.08.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Biotest AG ISIN: DE0005227235 können Sie bei EQS abrufen
Gesundheit , 522723 , BIO3 , XETR:BIO3